Two agonist antibodies, namely urelumab (BMS-663613) and utomilumab (PF-05082566), can be used in synergy with anti-CD20 and anti-PD-1 mAbs and are under study in clinical trials for the confirmation of their therapeutic effect on metastatic melanoma and advanced solid tumors, especially NSCLC and renal cell carcinoma (121). Here, PDCD1 is linked to metastatic melanoma.